drugset
drugset / Trial / NCT03865017

A Safety and Tolerability Study of GB301

NCT03865017 ↗

Phase 1/2 Unknown 20 enrolled VTBIO Co. LTD BHT Lifescience Austrailia Pty Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions at a single dose strength of GB301 in subjects with mild to moderate AD.

Timeline

Start
2019-12-01
Primary completion
2020-12-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Regulatory T cells Cell therapy 170000 cells/kg Intravenous

Indications

Alzheimer disease